Screener
Travere Therapeutics, Inc. TVTX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(37,102) | $(41,226) |
| Per share data | ||
| Basic and diluted: | ||
| Net loss per common share | $(0.40) | $(0.47) |
| Weighted average common shares outstanding | 91,868,862 | 88,355,973 |
| Comprehensive loss: | ||
| Net loss | $(37,102) | $(41,226) |
| Foreign currency translation gain (loss) | 447 | (686) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s EPS (basic)?
- Travere Therapeutics, Inc. (TVTX) reported EPS (basic) of -$0.40 in Q1 2026.
- How has Travere Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Travere Therapeutics, Inc.'s EPS (basic) increased by 14.9% year-over-year, from -$0.47 to -$0.40.
- What is the long-term trend for Travere Therapeutics, Inc.'s EPS (basic)?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s EPS (basic) has grown at a 10.4% compound annual growth rate (CAGR), from -$3.03 to -$4.08.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Travere Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude